Carbenz 150/450 Liquid Injection

Generic Name– Carboplatin
Drug Class– Antineoplastic agent
Carboplatin is a second-generation platinum compound which is used in the treatment of patients with ovarian cancer. It has also shown promising results in the treatment of small cell lung cancer, squamous cell carcinomas of the head and neck, and seminomas. It acts by inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links, thereby resulting in apoptosis and cell growth inhibition.
Dosage and Administration

  • Recommended dose when used as a single agent in treatment of recurrent ovarian cancer: 360 mg/m2 IV on day 1 every 4 weeks
  • Recommended dose when used in combination with cyclophosphamide in treatment of advanced ovarian cancer: 300 mg/m2 IV on day 1 every 4 weeks for 6 cycles followed by cyclophosphamide 600 mg/m2 IV on day 1 every 4 weeks for 6 cycles
  • Intermittent courses of carboplatin should not be repeated until the neutrophil count is at least 2,000 and the platelet count is at least 100,000

Dosage Form and Strengths

  • Supplied as a single use vial containing aqueous solution for intravenous infusion<
  • Available as 150mg and 450mg for injection


Carbenz 150/450 (Carboplatin for injection) is a liquid injection containing active drug concentrate for intravenous use.

Indications & Usage

Carboplatin is indicated for:

  • Initial Treatment of Advanced Ovarian Carcinoma
  • Secondary Treatment of Recurrent Ovarian Carcinoma

Clinical Efficacy

  • Produces clinical complete response rates in initial treatment of advanced ovarian cancer
  • Effective and well tolerated in combination with other chemotherapeutic agents used for the treatment of recurrent ovarian cancer
  • Shows overall objective response rates of 44% to 75% when used in combination with cyclophosphamide
  • Reduces the risk of severe toxicities such as neurotoxicity, myelotoxicity, alopecia, and cardio toxicity¬†associated with use of platinum based therapies

Safety Information

Adverse Reactions

  • The most common adverse effects that occur after treatment with carboplatin are nausea, vomiting, nephrotoxicity, peripheral neuropathy, pain, asthenia, alopecia, thrombocytopenia, neutropenia, leucopenia and anemia


  • It is contraindicated in patients with a history of severe allergic reactions to cisplatin or other platinum-containing compounds and severe bone marrow depression or significant bleeding

Special Precautions

  • Peripheral blood counts should be frequently monitored during and after treatment with carboplatin to determine bone marrow suppression related toxicity
  • Consider dose reduction in patients who have received prior platinum based therapy, especially regimens such as cisplatin and in patients with impaired kidney function
  • Caution should be used while administering carboplatin in combination with amino glycosides due to increased risk of renal and audiologic toxicity, especially in pediatric patients
  • Carboplatin can induce nausea and vomiting, therefore premedication with antiemetic is essential
  • Monitor loss of vision and allergic reactions including anaphylaxis in patients previously exposed to platinum therapy
  • Determine the risk of neurotoxicity, as its incidence increases in patients older than 65 years and in patients previously treated with cisplatin
  • Avoid contact of carboplatin with aluminium as it can react with carboplatin causing precipitate formation and loss of potency.
  • Women of childbearing potential should be advised to use effective contraceptives for avoiding pregnancy.
  • Breast-feeding be discontinued, if the mother is administered with carboplatin